Investor Presentaiton
Oncology
Hematology
Cell Therapy
Immunology
Cardiovascular
Opdivo (anti-PD1)
Metastatic Trials
Indication
Phase/Study
# of Patients
Design
•
1L MIUC
Phase III CheckMate -901
-
N = 1,290
PD-L1+ & cis-ineligible: Opdivo 1 mg/kg + Yervoy 3 mg/kg Q3W up to
4 cycles followed by Opdivo 480 mg Q4W vs SOC chemotherapy
Cis-eligible: Opdivo 360 mg in combination with chemotherapy Q3W
vs SOC chemotherapy
Primary:
PFS, OS in cis-eligible patients
Endpoints
OS in PD-L1+ (>=1%) & cis-ineligible
2L RCC SC
Phase III CheckMate -67T
-
• Opdivo +rHuPH20 SC
Opdivo IV
N = 454
Primary:
Cavgd28 (Opdivo serum concentration)
⚫ Cminss
Status
CT Identifier
Positive topline results in cis-eligible in July 2023
Data presented at ESMO 2023 as a Late Breaker in the Presidential
Symposium
• Cis-eligible data published in NEJM October 2023
• Projected data readout 2024 in cis-ineligible
Did not meet primary OS endpoint in PD-L1+
NCT03036098
ll Bristol Myers Squibb™ | Q3 2023 Results
•
Key secondary: ORR
•
Positive topline results in October 2023
NCT04810078
Not for Product Promotional Use
35View entire presentation